Literature DB >> 9461328

Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods.

H Lecoeur1, E Ledru, M C Prévost, M L Gougeon.   

Abstract

The present article compares the reliability of four previously described cytofluorometric methods of apoptosis quantification for phenotyping apoptotic human lymphocytes. Each of these assays detects distinct cellular alterations of the apoptotic process. Alteration in plasma membrane integrity can be evaluated following 7-AAD incorporation and the translocation of phosphatidylserine from the inner to the outer layer of the plasma membrane can be detected through the FITC annexin V staining. DNA strand breaks in apoptotic nuclei can be evidenced by the ISNT assay and finally morphological modifications can be followed with FSC/SSC criteria. Comparative analysis of apoptosis in cultured PBMC from HIV-infected patients considering the FSC/SSC parameters, 7-AAD stainability and annexin V fixation revealed that the latter identifies early apoptotic cells, also characterized as 7-AAD(low) with a reduced FSC. Moreover these three methods proved to be reliable and gave statistically similar results when combined with cell surface detection of antigens such as CD4, CD8 and CD19 by specific mAbs. Importantly, the 7-AAD assay easily allowed the identification of debris/apoptotic bodies, which were still stained by anti-cell surface mAbs and might therefore significantly distort the apoptosis percentage in a given lymphocyte subset. In the present report we also point out that the ISNT assay is not appropriate for phenotyping apoptotic lymphocytes in PBMC. Indeed it can particularly underestimate the rate of apoptosis in the B-cell subset. This was found to be related to the apoptosis-associated decrease in cell surface antigen expression, which is dramatically exacerbated in the ISNT assay because of the stripper effect of ethanol used for cell permeabilization. Finally, we propose a three step analytical strategy to accurately phenotype apoptotic peripheral human lymphocytes. It includes two gating steps performed on FSC/SSC criteria and 7-AAD/FSC parameters to eliminate monocytes, granulocytes and debris-apoptotic bodies, the third step being the phenotyping step itself, performed in dual or triple staining experiments. Altogether these observations emphasize that it is essential to assess critically the ability of a cytofluorometric method to phenotype apoptotic cells in complex lymphoid populations and that inaccurate identification of cell subsets undergoing apoptosis can be readily overcome by gating properly the lymphoid population, and using assays which preserve cell surface structure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9461328     DOI: 10.1016/s0022-1759(97)00138-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  37 in total

1.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

2.  Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease.

Authors:  Natasa Kustrimovic; Emanuela Rasini; Massimiliano Legnaro; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-29       Impact factor: 4.147

3.  IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells.

Authors:  Hélène Le Buanec; Marie-Lise Gougeon; Alexis Mathian; Pierre Lebon; Jean-Michel Dupont; Gabriel Peltre; Patrice Hemon; Michel Schmid; Bernard Bizzini; Thomas Künding; Arsène Burny; Armand Bensussan; Zahir Amoura; Robert C Gallo; Daniel Zagury
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

5.  Are mesenchymal stromal cells from children resistant to apoptosis?

Authors:  H Dimitriou; Ch Perdikogianni; G Martimianaki; D M Choumerianou; J Pelagiadis; M Kalmanti
Journal:  Cell Prolif       Date:  2009-04-28       Impact factor: 6.831

6.  Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines.

Authors:  Xiaoli Shen; Ramanjaneya V R Mula; B Mark Evers; Miriam Falzon
Journal:  Regul Pept       Date:  2007-01-10

7.  Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome.

Authors:  Dina M Aresvik; Torstein Øverland; Kari Lima; Rolf D Pettersen; Tore G Abrahamsen
Journal:  J Clin Immunol       Date:  2018-12-19       Impact factor: 8.317

8.  Transcription factor GATA-3 is essential for lens development.

Authors:  Atsuko Maeda; Takashi Moriguchi; Michito Hamada; Manabu Kusakabe; Yuki Fujioka; Takako Nakano; Keigyou Yoh; Kim-Chew Lim; James Douglas Engel; Satoru Takahashi
Journal:  Dev Dyn       Date:  2009-09       Impact factor: 3.780

9.  Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase.

Authors:  Hongwei Si; Dongmin Liu
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

10.  Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis.

Authors:  Baoying Liu; Zhuqing Li; Sankaranarayana P Mahesh; Seth Pantanelli; Frank S Hwang; Willie O Siu; Robert B Nussenblatt
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.